A method for preparing an edoxaban tosylate intermediate
During the preparation of the edoxaban toluenesulfonic acid intermediate, the reaction of compound 4 and compound 3 under the action of alkali and the amine ester exchange was solved, and the problems of curing and impurity generation were achieved, and high purity and high yields were achieved. The preparation is suitable for industrial production.
Patent Information
- Application Number
- CN202411222988.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-03
AI Technical Summary
There are curing problems and impurities in the preparation process of edoxaban toluenesulfonate intermediate, which leads to difficulty in stirring, low purity and low yield. It is difficult for existing methods to completely solve these problems, especially in industrial production.
Compound 2 is formed by reacting compound 4 and compound 3 under the action of alkali in the solvent system, and amine ester exchange with 2-amino-5-chloropyridine under the action of alkali, forming an edoxaban toluenesulfonic acid intermediate. The organic tertiary base is used as the base, and the reaction temperature and molar ratio are controlled, and the process is carried out to obtain a high-purity product.
It avoids curing problems, improves reaction yield and product purity, simplifies operations, is suitable for industrial production, and has a product purity of more than 99%.
Smart Images

Figure CN118724801B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing an edoxaban tosylate intermediate, and belongs to the technical field of organic synthesis. Background Art
[0002] With the increasing incidence of cardiovascular diseases, people's demand for anticoagulants is increasing, and FXa inhibitors are gradually becoming the development trend of anticoagulants. Among them, edoxaban tosylate is a new oral anticoagulant that can prevent the formation of blood clots by inhibiting the activation of prothrombin.
[0003] Edoxaban tosylate, chemical name N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4, 5, 6, 7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)oxadiamide p-toluenesulfonate monohydrate was developed by Daiichi Sankyo Co., Ltd. and was first launched in Japan in April 2011 for the treatment of venous thromboembolism (VTE). In January 2015, it was approved in the United States for reducing the risk of stroke and dangerous thrombosis (systemic embolism) in patients with atrial fibrillation caused by non-valvular heart disease. It can also be used to prevent and treat venous thromboembolism in patients undergoing total knee replacement, total hip replacement, and hip fracture surgery. Or for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, previous history of stroke or transient ischemic attack (TIA)). Or for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and for the prevention of recurrence of deep vein thrombosis and pulmonary embolism in adults.
[0004] PCT patent application WO2007032498A1 discloses a method for preparing edoxaban tosylate (Compound 5) which is mainly synthesized via the following route:
[0005] ;
[0006] During the synthesis of the edoxaban tosylate intermediate (Compound 1), solidification problems occurred, stirring was difficult, and it was not suitable for scale-up production. At the same time, a large amount of impurity compound 9 was produced during the preparation process as shown below:
[0007] ;
[0008] The impurity (compound 9) is difficult to remove, which affects the purity of the compound and results in a lower yield.
[0009] In Chinese patent CN102348688B, the solidification problem in the preparation process of compound 1 is prevented by adding alkali in batches and changing the feeding method, but it is found in actual operation that this method is still difficult to prevent the occurrence of solidification. Chinese patent CN105753888B discloses a method for preparing compound 1, which prevents solidification by adding triethylamine to compound 6, then adding compound 4, and then adding triethylamine again, but the method system is relatively viscous and stirring is still difficult, and the problem is not completely solved. Chinese patent CN108484641B proposes to add an appropriate amount of specific ionic liquid and select a combination of triethylamine and pyridine in a specific ratio as a base to prevent solidification during the synthesis of compound 1. This method is relatively cumbersome to operate, and a large amount of environmentally unfriendly pyridine is used to cause pollution. Therefore, it is of great value to develop a new method for preparing edoxaban tosylate intermediate (compound 1). Summary of the invention
[0010] The present invention aims at the deficiencies in the prior art and provides a method for preparing an edoxaban tosylate intermediate, which avoids the generation of solidification problems, increases the reaction yield, simplifies post-processing operations, and improves product purity.
[0011] The technical solution of the present invention to solve the above technical problems is as follows: a method for preparing an edoxaban tosylate intermediate, the preparation method comprising:
[0012] S1. In a solvent system, compound 4 reacts with compound 3 under the action of a base to obtain compound 2;
[0013] S2. In a solvent system, compound 2 is subjected to amine ester exchange with 2-amino-5-chloropyridine under the action of a base to generate compound 1, wherein compound 1 is the edoxaban tosylate intermediate;
[0014] The structural formula of the compound 4 is: , Boc represents tert-butyloxycarbonyl;
[0015] The structural formula of the compound 3 is: ;
[0016] The structural formula of the compound 2 is: ;
[0017] The structural formula of the compound 1 is: .
[0018] Furthermore, in step S1 and step S2, the base is an organic tertiary base.
[0019] Furthermore, in step S1 and step S2, the base is at least one of alkylamine, 1-(C1-C3 alkyl)pyrrolidine, 1-(C1-C3 alkyl)piperidine, 4-(C1-C3 alkyl)morpholine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, di(C1-C3 alkyl)aniline and 4-di(C1-C3 alkyl)aminopyridine.
[0020] Preferably, in step S1 and step S2, the base is at least one of triethylamine, 4-methylmorpholine, and N,N-diisopropylethylamine.
[0021] Furthermore, the reaction temperature of step S1 is -10~50°C, and the reaction temperature of step S2 is 15~80°C.
[0022] Preferably, the reaction temperature of step S1 is -10~25°C; the reaction temperature of step S2 is 60~75°C.
[0023] Furthermore, in step S1, the molar ratio of compound 4 to compound 3 is 1:(1.10-3.00); the molar ratio of compound 3 to the base is 1:(1.00-2.00).
[0024] Furthermore, in step S2, the molar ratio of compound 2 to 2-amino-5-chloropyridine is 1:(0.95-2.00); the molar ratio of compound 2 to the base is 1:(0.1-4.00).
[0025] Furthermore, the solvent used in the reaction process of step S1 and step S2 is at least one of C2-C4 nitrile, tetrahydrofuran, 2-methyltetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, toluene and dichloromethane.
[0026] Further, after the reaction in step S2 is completed, a post-treatment operation is performed to obtain compound 1, and the post-treatment operation is:
[0027] After the reaction, the reaction system was cooled to 15-25°C, water was added, and then cooled to 0-10°C for crystallization. The solid was collected by solid-liquid separation and dried under reduced pressure at 50-60°C to obtain compound 1.
[0028] The beneficial effects of the present invention are:
[0029] (1) The present invention uses compound 4 as the starting material and constructs a clear reaction system by redesigning the route, thereby preventing the violent precipitation of raw materials and products, solving the problem of easy solidification and difficult stirring solidification during the reaction, and is more conducive to application in industrial production.
[0030] (2) The product purity obtained by this route is higher than 99%, which is much higher than the yield and purity of conventional technologies. In addition, the operation is simple and suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is the HPLC spectrum of compound 1 prepared in Example 1. DETAILED DESCRIPTION
[0032] The specific implementation of the present invention is described in detail below. The present invention can be implemented in many other ways than those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention, so the present invention is not limited by the specific embodiments disclosed.
[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used are only for describing specific embodiments and are not intended to limit the present invention.
[0034] A method for preparing an edoxaban tosylate intermediate, the preparation method comprising:
[0035] ;
[0036] Here, Boc represents tert-butyloxycarbonyl.
[0037] S1. Compound 4 is used as a raw material, and compound 3 (methyl oxalyl chloride) is added in an aprotic solvent to form a clear solution, and then a base is added to obtain compound 2 through a nucleophilic substitution reaction;
[0038] S2. Compound 2 is used as a raw material, and compound 3 and a base are added in an aprotic solvent, followed by the addition of 2-amino-5-chloropyridine to form compound 1 through amine ester exchange, wherein compound 1 is the edoxaban tosylate intermediate.
[0039] Specifically, in step S1 and step S2, the base is an organic tertiary base.
[0040] More specifically, in step S1 and step S2, the base is at least one of alkylamine, 1-(C1-C3 alkyl)pyrrolidine, 1-(C1-C3 alkyl)piperidine, 4-(C1-C3 alkyl)morpholine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), di(C1-C3 alkyl)aniline and 4-di(C1-C3 alkyl)aminopyridine.
[0041] Preferably, in step S1 and step S2, the base is at least one of triethylamine, 4-methylmorpholine, and N,N-diisopropylethylamine.
[0042] Specifically, the reaction temperature of step S1 is -10 to 50°C; preferably -10 to 25°C.
[0043] Specifically, the reaction temperature of step S2 is 15-80°C; preferably 60-75°C.
[0044] Specifically, in step S1, the molar ratio of compound 4 to compound 3 is 1:(1.10-3.00); the molar ratio of compound 3 to the base is 1:(1.00-2.00).
[0045] Specifically, in step S2, the molar ratio of compound 2 to 2-amino-5-chloropyridine is 1:(0.95-2.00); the molar ratio of compound 2 to the base is 1:(0.1-4.00).
[0046] Specifically, the solvent used in the reaction process of step S1 and step S2 is at least one of C2-C4 nitrile, tetrahydrofuran, 2-methyltetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, toluene and dichloromethane.
[0047] Preferably, the solvent is acetonitrile or dichloromethane.
[0048] Specifically, after the reaction of preparing compound 2 in step S1 is completed, compound 2 can be purified through post-treatment to be used in step S2, or the reaction of step S2 can be directly carried out without post-treatment.
[0049] Specifically, after the reaction in step S2 is completed, a post-treatment operation is performed to obtain compound 1, and the post-treatment operation is as follows: after the reaction is completed, the reaction system is cooled to 15-25°C, water is added, and then cooled to 0-10°C for crystallization, solid-liquid separation is performed to collect the solid, and the compound 1 is obtained by drying under reduced pressure at 50-60°C.
[0050] Example 1
[0051] (1) Preparation of compound 2 (chemical name: methyl {[(1S,2R,4S)-2-{[(tert-butyloxy)carbonyl]amino}-4-(dimethylaminocarbonyl)cyclohexyl]carbamoyl}formate):
[0052] Under N2 protection, compound 4 (20.00 g, 53.27 mmol) and 100.00 g of acetonitrile were added to a dry 250 mL three-necked flask, and the reaction system was cooled to -10~0°C; then oxalyl chloride monomethyl ester (9.79 g, 79.91 mmol) was added dropwise, and after the dropwise addition, the system was a clear solution, and then triethylamine (10.78 g, 106.55 mmol) was added dropwise. After the dropwise addition, the temperature was raised to 15~25°C for reaction. After the reaction was completed by HPLC monitoring, the system was concentrated at 45°C until there was no fraction, and water (100.00 g) was added to the concentrated residue for slurrying for 5 hours. Afterwards, the filter cake was collected by filtration and dried under reduced pressure at 50°C to obtain 18.60 g of compound 2, with a yield of 94% and a purity of 99.3%.
[0053] By high-resolution mass spectrometry (HR-ESI-MS), nuclear magnetic resonance spectroscopy ( 1 H-NMR), carbon nuclear magnetic resonance spectroscopy ( 13 C-NMR) confirmed the structure of compound 2. ESI-HRMS: C 17 H 29 O6N3[M + H] + : 372.2129, test data: 372.2131.
[0054] 1 H-NMR(400MHz,DMSO-d6): 8.464 (d, 1H, J=7.6Hz), 6.951 (d, 1H, J=7.2Hz), 3.912-3.894(m, 1H), 3.755-3.714 (m, 4H), 2.987 (s, 3H), 2.942-2.912 (m, 1H), 2.782 (s, 3H), 1.796-1.502 (m, 5H), 1.426-1.356 (m, 10H). 13 C-NMR (100MHz, DMSO-d6) δ:174.504, 161.529, 156.460, 156.345, 78.679, 53.381, 50.641, 48.350,36.938, 35.414, 33.038, 32.760, 28.697, 27.700, 25.161.
[0055] (2) Preparation of compound 1 (chemical name: (1R, 2S, 5S)-2-({2-[(5-chloropyridin-2-yl)amino]-2-oxoacetyl}amino)-5-(dimethylaminocarbonyl)cyclohexylcarbamic acid tert-butyl ester):
[0056] Under N2 protection, compound 2 (15.00 g, 40.38 mmol), 2-amino-5-chloropyridine (5.71 g, 44.42 mmol), and acetonitrile (60.00 g) were added to a 250 mL three-necked flask, stirring was started and the temperature was raised to 60°C, and then triethylamine (4.09 g, 40.38 mmol) was added dropwise to the reaction system. After the addition was completed, the reaction was carried out at 60°C. After the reaction was completed by HPLC monitoring, the reaction system was cooled to 25°C, water (60.00 g) was added, and then the temperature was cooled to 10°C for crystallization, filtered, and the filter cake was collected and dried under reduced pressure at 50°C to obtain 17.58 g of compound 1 with a purity of 99.7% and a yield of 93%. The HPLC spectrum of compound 1 is shown in Figure 1 As shown, the relevant data of HPLC spectrum are shown in Table 1.
[0057] Table 1 HPLC chromatogram data
[0058]
[0059] By high-resolution mass spectrometry (HR-ESI-MS), nuclear magnetic resonance spectroscopy ( 1 H-NMR), carbon nuclear magnetic resonance spectroscopy ( 13 C-NMR) confirmed the structure of compound 1. ESI-HRMS: C 21 H 30 O5ClN5[M + H] + :468.2008, test data:468.2011.
[0060] 1 H-NMR(400MHz,DMSO-d6): 10.248 (s, 1H), 8.670 (d, 1H, J=8.2 Hz), 8.466(dd, 1H, J1=2.4 Hz, J2=0.8 Hz), 8.066-8.012(m, 2H), 7.039 (d, 1H, J=6.4 Hz),3.946-3.920 (m, 1H),3.843-3.794 (m, 1H), 2.994-2.907 (m, 4H), 2.798 (s, 3H),1.886-1.527 (m, 5H), 1.480-1.245(m, 10H). 13C-NMR (100MHz, DMSO-d6) δ: 174.504,158.904, 158.865, 156.345, 149.139, 147.433, 138.886, 127.243, 115.552,78.736, 50.746, 48.628, 36.918, 35.433, 33.076,32.721, 28.697, 27.681,25.324.
[0061] Example 2
[0062] (1) Preparation of compound 2 (chemical name: methyl {[(1S,2R,4S)-2-{[(tert-butyloxy)carbonyl]amino}-4-(dimethylaminocarbonyl)cyclohexyl]carbamoyl}formate):
[0063] Under N2 protection, compound 4 (20.00 g, 53.27 mmol) and 60.00 g of acetonitrile were added to a dry 250 mL three-necked flask, and the reaction system was cooled to -10~0°C; then oxalyl chloride monomethyl ester (7.18 g, 58.60 mmol) was added dropwise, and after the dropwise addition, the system was a clear solution, and then triethylamine (11.86 g, 117.20 mmol) was added dropwise. After the dropwise addition, the temperature was raised to 45~50°C for reaction. After the reaction was completed by HPLC monitoring, the system was concentrated at 40°C until there was no fraction, and water (60.00 g) was added to the concentrated residue and stirred for 5 h. Afterwards, the filter cake was collected by filtration and dried under reduced pressure at 60°C to obtain 18.01 g of compound 2, with a yield of 91% and a purity of 99.5%.
[0064] (2) Preparation of compound 1 (chemical name: (1R, 2S, 5S)-2-({2-[(5-chloropyridin-2-yl)amino]-2-oxoacetyl}amino)-5-(dimethylaminocarbonyl)cyclohexylcarbamic acid tert-butyl ester):
[0065] Under N2 protection, compound 2 (10.00 g, 26.92 mmol), 2-amino-5-chloropyridine (10.00 g, 26.92 mmol) and acetonitrile (60.00 g) were added to a 250 mL three-necked flask, the stirring was started and the temperature was raised to 75-80 °C, and then triethylamine (0.27 g, 2.692 mmol) was added dropwise to the reaction system. After the dropwise addition, the reaction was carried out at 75-80 °C. After the reaction was completed by HPLC monitoring, the reaction system was cooled to 15 °C, water (40.00 g) was added, and then cooled to 0 °C for crystallization, filtered, and the filter cake was collected and dried under reduced pressure at 50 °C to obtain 11.97 g of compound 1 with a purity of 99.3% and a yield of 95%.
[0066] Example 3
[0067] (1) Preparation of compound 2 (chemical name: methyl {[(1S,2R,4S)-2-{[(tert-butyloxy)carbonyl]amino}-4-(dimethylaminocarbonyl)cyclohexyl]carbamoyl}formate):
[0068] Under N2 protection, compound 4 (20.00 g, 53.27 mmol) and 100.00 g of dichloromethane were added to a dry 250 mL three-necked flask, and the reaction system was cooled to -10~0°C; then oxalyl chloride monomethyl ester (19.58 g, 159.82 mmol) was added dropwise, and the system was a clear solution after the addition was completed. Then 4-methylmorpholine (24.25 g, 239.73 mmol) was slowly added. After the addition was completed, the reaction was carried out at -10°C. After the reaction was completed by HPLC monitoring, the system was concentrated at 35~40°C, and water (60.00 g) was added to the concentrated residue and stirred for 6 h. After filtration, the filter cake was collected and dried under reduced pressure at 60°C to obtain 18.40 g of compound 2, with a yield of 93% and a purity of 99.2%.
[0069] (2) Preparation of compound 1 (chemical name: (1R, 2S, 5S)-2-({2-[(5-chloropyridin-2-yl)amino]-2-oxoacetyl}amino)-5-(dimethylaminocarbonyl)cyclohexylcarbamic acid tert-butyl ester):
[0070] Under N2 protection, compound 2 (10.00 g, 26.92 mmol), 2-amino-5-chloropyridine (3.46 g, 26.92 mmol), and dichloromethane (50.00 g) were added to a 250 mL three-necked flask, the stirring was started and the temperature was raised to 35-40 °C, and then 4-methylmorpholine (10.89 g, 107.69 mmol) was slowly added to the reaction system. After the addition was completed, the reaction was carried out at 35-40 °C. After the reaction was completed by HPLC monitoring, the reaction system was concentrated to no fraction, water (40.00 g) and acetonitrile (20.00 g) were added and stirred for 4 h, then the temperature was lowered to 0 °C for crystallization, filtered, the filter cake was collected, and dried under reduced pressure at 50 °C to obtain 11.46 g of compound 1 with a purity of 99.4% and a yield of 91%.
[0071] Example 4
[0072] (1) Preparation of compound 2 (chemical name: methyl {[(1S,2R,4S)-2-{[(tert-butyloxy)carbonyl]amino}-4-(dimethylaminocarbonyl)cyclohexyl]carbamoyl}formate):
[0073] Under N2 protection, compound 4 (20.00 g, 53.27 mmol) and N,N-dimethylformamide (100.00 g) were added to a dry 250 mL three-necked flask, and the reaction system was cooled to -10~0°C; then oxalyl chloride monomethyl ester (9.79 g, 79.91 mmol) was added dropwise, and after the addition, the system was a clear solution, and then N,N-diisopropylethylamine (10.33 g, 79.91 mmol) was slowly added. After the addition, the temperature was raised to 15°C for reaction. After the reaction was completed by HPLC monitoring, the system was concentrated at 80°C, and water (60.00 g) was added to the concentrated residue and stirred for 6 h. After filtration, the filter cake was collected and dried under reduced pressure at 60°C to obtain 17.81 g of compound 2, with a yield of 90% and a purity of 99.0%.
[0074] (2) Preparation of compound 1 (chemical name: (1R, 2S, 5S)-2-({2-[(5-chloropyridin-2-yl)amino]-2-oxoacetyl}amino)-5-(dimethylaminocarbonyl)cyclohexylcarbamic acid tert-butyl ester):
[0075] Under N2 protection, compound 2 (9.64 g, 25.95 mmol), 2-amino-5-chloropyridine (6.67 g, 51.91 mmol), and N,N-dimethylformamide (48.20 g) were added to a 250 mL three-necked flask, stirring was started and the system temperature was maintained at 15°C, and then N,N-diisopropylethylamine (13.42 g, 103.81 mmol) was added to the reaction system. After the addition was completed, the reaction was carried out at 15°C. After the reaction was completed by HPLC monitoring, water (40.00 g) was added to the reaction system at 15°C, and then the temperature was lowered to 0°C for crystallization, filtered, and the filter cake was collected and dried under reduced pressure at 50°C to obtain 11.17 g of compound 1 with a purity of 99.5% and a yield of 92%.
[0076] Example 5
[0077] (1) Preparation of compound 2 (chemical name: methyl {[(1S,2R,4S)-2-{[(tert-butyloxy)carbonyl]amino}-4-(dimethylaminocarbonyl)cyclohexyl]carbamoyl}formate):
[0078] Under N2 protection, compound 4 (20.00 g, 53.27 mmol) and 100.00 g of acetonitrile were added to a dry 250 mL three-necked flask, and the reaction system was cooled to -10~0°C; then oxalyl chloride monomethyl ester (9.79 g, 79.91 mmol) was added dropwise, and after the addition, the system was a clear solution, and then 4-methylmorpholine (16.17 g, 159.82 mmol) was slowly added. After the addition, the reaction was carried out at 0°C. After the reaction was completed by HPLC monitoring, water (100.00 g) was added to the system and stirred for 5 hours. Afterwards, the filter cake was collected by filtration and dried under reduced pressure at 50°C to obtain 17.61 g of compound 2, with a yield of 89% and a purity of 99.2%.
[0079] (2) Preparation of compound 1 (chemical name: (1R, 2S, 5S)-2-({2-[(5-chloropyridin-2-yl)amino]-2-oxoacetyl}amino)-5-(dimethylaminocarbonyl)cyclohexylcarbamic acid tert-butyl ester):
[0080] Under N2 protection, compound 2 (10.00 g, 26.92 mmol), 2-amino-5-chloropyridine (3.81 g, 29.62 mmol) and acetonitrile (30.00 g) were added to a 250 mL three-necked flask, the stirring was started and the temperature was raised to 40 °C, and then 4-methylmorpholine (5.45 g, 53.85 mmol) was added dropwise to the reaction system. After the dropwise addition, the reaction was carried out at 40 °C. After the reaction was completed by HPLC monitoring, the reaction system was cooled to 20 °C, water (60.00 g) was added, and then the temperature was cooled to 5 °C for crystallization, filtered, and the filter cake was collected and dried under reduced pressure at 50 °C to obtain 11.72 g of compound 1 with a purity of 99.2% and a yield of 93%.
[0081] Comparative Example 1
[0082] Compound 2 was prepared by the same method as in Example 1, except that the amount of monomethyl oxalyl chloride (Compound 3) was increased so that the molar ratio of Compound 4 to Compound 3 was 1:4.
[0083] In this comparative example 1, the yield of compound 2 is 82%.
[0084] It can be seen from the experimental data of Example 1 and Comparative Example 1 that if the dosage ratio of monomethyl oxalyl chloride (Compound 3) is increased, the yield of Compound 2 will decrease, because the concentration of monomethyl oxalyl chloride is too high, resulting in a strong acidity of the system. Before the addition of the base, a byproduct of the deprotection of the Boc protecting group of Compound 4 has been produced in the reaction system, resulting in a low conversion rate. Therefore, the use of the proportion defined in the present invention is more conducive to obtaining a high-yield product.
[0085] Comparative Example 2
[0086] Compound 1 was prepared by conventional methods. The specific preparation process is as follows:
[0087] Under nitrogen protection, triethylamine (69 mL) was added to a suspension (550 ml) of tert-butyl {(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl}carbamate oxalate (100.1 g) in acetonitrile at 10°C. Ethyl [5-chloropyridin-2-yl]amino] (oxo)acetate monohydrochloride (84.2 g) was added thereto at this temperature, and after stirring for 0.5 h, triethylamine (100 mL) was slowly added to the system, and the reaction was stirred at 60°C for 5 h, and then stirred at 15-25°C for 10 hours. Water (550 g) was added to the reaction solution, and stirred at 10°C for 1.5 hours. The deposited crystals were collected by filtration and dried to obtain compound 1 with a yield of 86% and a purity of 95%.
[0088] It can be seen from the experimental results of Examples 1-5 and Comparative Example 2 that the yield and purity of the edoxaban tosylate intermediate (Compound 1) prepared by the preparation method of the present invention in Examples 1-5 are higher. However, Comparative Example 2 adopts a conventional method, and solidification occurs in the system during the preparation process, which ultimately affects the stirring effect and leads to the generation of a large amount of impurity compound 9. The impurity is difficult to remove, which seriously affects the purity and yield of the final product. This is a preparation method that is difficult to achieve industrial scale-up. The process route reaction of the preparation method of the present invention is simple and easy to operate, avoiding the solidification problem caused by the existing route and the problem of instability of multiphase reaction scale-up production, and is more suitable for industrial production. The purity of the obtained target compound is significantly higher than that of the existing route.
[0089] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are exhaustively listed. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0090] For those skilled in the art, several modifications and improvements may be made without departing from the concept of the present invention, all of which belong to the protection scope of the present invention. The protection scope of the present invention shall be based on the attached claims.
Claims
1. A method for preparing an edoxaban tosylate intermediate, characterized in that: The preparation method is: S1, using compound 4 as a raw material, adding compound 3 in an aprotic solvent to form a clear solution, then adding a base to obtain compound 2 through a nucleophilic substitution reaction; the reaction temperature of step S1 is -10~50°C; S2. In a solvent system, compound 2 is subjected to amine ester exchange with 2-amino-5-chloropyridine under the action of a base to generate compound 1, wherein compound 1 is the edoxaban tosylate intermediate; the reaction temperature of step S2 is 15-80° C.; In step S1 and step S2, the base is at least one of triethylamine, 4-methylmorpholine, and N,N-diisopropylethylamine; In step S1, the molar ratio of compound 4 to compound 3 is 1:(1.10-3.00); the molar ratio of compound 3 to base is 1:(1.00-2.00); In step S2, the molar ratio of compound 2 to 2-amino-5-chloropyridine is 1:(0.95-2.00); the molar ratio of compound 2 to the base is 1:(0.1-4.00); After the reaction in step S2 is completed, a post-treatment operation is performed to obtain compound 1, and the post-treatment operation is: After the reaction is completed, the reaction system is cooled to 15-25°C, water is added, and then cooled to 0-10°C for crystallization, and the solid is collected by solid-liquid separation and dried under reduced pressure at 50-60°C to obtain compound 1; The structural formula of the compound 4 is: , Boc represents tert-butyloxycarbonyl; The structural formula of the compound 3 is: ; The structural formula of the compound 2 is: ; The structural formula of the compound 1 is: .
2. A method for preparing an edoxaban tosylate intermediate according to claim 1, characterized in that: The reaction temperature of step S1 is -10~25°C; the reaction temperature of step S2 is 60~75°C.
3. The method for preparing an edoxaban tosylate intermediate according to claim 1, characterized in that: The solvent used in the reaction process of step S1 and step S2 is at least one of C2-C4 nitrile, tetrahydrofuran, 2-methyltetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, toluene and dichloromethane.
Citation Information
Cited By
Quality control method for indissolvable impurities in preparation of esdoxaban tosylate
CN121324562A
